메뉴 건너뛰기




Volumn 6, Issue 12, 2016, Pages 1352-1365

Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; B RAF KINASE; CETUXIMAB; FIRTECAN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; INDOLE DERIVATIVE; SULFONAMIDE;

EID: 85007391933     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0050     Document Type: Article
Times cited : (195)

References (32)
  • 1
  • 3
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3    De Schutter, J.4    Biesmans, B.5    Fountzilas, G.6
  • 4
    • 79958817037 scopus 로고    scopus 로고
    • E t al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
    • Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, e t al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32.
    • (2011) Cancer , vol.117 , pp. 4623-4632
    • Tran, B.1    Kopetz, S.2    Tie, J.3    Gibbs, P.4    Jiang, Z.Q.5    Lieu, C.H.6
  • 5
    • 79956298812 scopus 로고    scopus 로고
    • Cetuximab plus irinotecan, fl uorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
    • Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fl uorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
    • (2011) J Clin Oncol , vol.29 , pp. 2011-2019
    • Van Cutsem, E.1    Kohne, C.H.2    Lang, I.3    Folprecht, G.4    Nowacki, M.P.5    Cascinu, S.6
  • 6
    • 67649652208 scopus 로고    scopus 로고
    • BRAF mutation in metastatic colorectal cancer
    • Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-9.
    • (2009) N Engl J Med , vol.361 , pp. 98-99
    • Tol, J.1    Nagtegaal, I.D.2    Punt, C.J.3
  • 7
    • 84908219463 scopus 로고    scopus 로고
    • Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
    • Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 2014; 13: 164-71.
    • (2014) Clin Colorectal Cancer , vol.13 , pp. 164-171
    • Morris, V.1    Overman, M.J.2    Jiang, Z.Q.3    Garrett, C.4    Agarwal, S.5    Eng, C.6
  • 8
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma
    • Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010; 467: 596-9.
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3    Zhang, J.4    Ibrahim, P.N.5    Cho, H.6
  • 10
    • 84879177690 scopus 로고    scopus 로고
    • Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation
    • Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013; 23: 1277-83.
    • (2013) Thyroid , vol.23 , pp. 1277-1283
    • Kim, K.B.1    Cabanillas, M.E.2    Lazar, A.J.3    Williams, M.D.4    Sanders, D.L.5    Ilagan, J.L.6
  • 11
    • 84883875497 scopus 로고    scopus 로고
    • Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation
    • Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013; 31: e351-2.
    • (2013) J Clin Oncol , vol.31 , pp. e351-e352
    • Munoz, J.1    Schlette, E.2    Kurzrock, R.3
  • 12
    • 84951810474 scopus 로고    scopus 로고
    • Phase II pilot study of vemurafenib in patients with metastatic BRAFmutated colorectal cancer
    • Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAFmutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
    • (2015) J Clin Oncol , vol.33 , pp. 4032-4038
    • Kopetz, S.1    Desai, J.2    Chan, E.3    Hecht, J.R.4    O’Dwyer, P.J.5    Maru, D.6
  • 13
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3    Di Nicolantonio, F.4    Salazar, R.5    Zecchin, D.6
  • 14
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3    Coffee, E.M.4    Nishino, M.5    Cogdill, A.P.6
  • 15
    • 84927604543 scopus 로고    scopus 로고
    • Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
    • Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-20.
    • (2015) Clin Cancer Res , vol.21 , pp. 1313-1320
    • Yaeger, R.1    Cercek, A.2    O'reilly, E.M.3    Reidy, D.L.4    Kemeny, N.5    Wolinsky, T.6
  • 17
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3    Khayat, D.4    Bleiberg, H.5    Santoro, A.6
  • 18
    • 84863012433 scopus 로고    scopus 로고
    • Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
    • Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779-89.
    • (2012) Cancer Res , vol.72 , pp. 779-789
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3    Packman, K.4    Bradley, W.D.5    Lee, R.J.6
  • 19
    • 0034131260 scopus 로고    scopus 로고
    • Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay
    • Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000; 60: 3147-51.
    • (2000) Cancer Res , vol.60 , pp. 3147-3151
    • Han, S.Y.1    Kato, H.2    Kato, S.3    Suzuki, T.4    Shibata, H.5    Ishii, S.6
  • 20
    • 44249111440 scopus 로고    scopus 로고
    • EPIC: Phase III trial of cetuximab plus irinotecan after fl uoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    • Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fl uoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2311-2319
    • Sobrero, A.F.1    Maurel, J.2    Fehrenbacher, L.3    Scheithauer, W.4    Abubakr, Y.A.5    Lutz, M.P.6
  • 21
    • 44849083804 scopus 로고    scopus 로고
    • Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fl uorouracil
    • Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fl uorouracil. Ann Oncol 2008; 19: 1141-5.
    • (2008) Ann Oncol , vol.19 , pp. 1141-1145
    • Pfeiffer, P.1    Nielsen, D.2    Bjerregaard, J.3    Qvortrup, C.4    Yilmaz, M.5    Jensen, B.6
  • 22
    • 48349134539 scopus 로고    scopus 로고
    • Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial
    • Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial. Br J Cancer 2008; 99: 455-8.
    • (2008) Br J Cancer , vol.99 , pp. 455-458
    • Martin-Martorell, P.1    Rosello, S.2    Rodriguez-Braun, E.3    Chirivella, I.4    Bosch, A.5    Cervantes, A.6
  • 23
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-67.
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3    Tsao, C.C.4    Lemos, R.5    Dayyani, F.6
  • 24
    • 80051625929 scopus 로고    scopus 로고
    • Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    • Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
    • (2011) J Clin Oncol , vol.29 , pp. 3085-3096
    • Wagle, N.1    Emery, C.2    Berger, M.F.3    Davis, M.J.4    Sawyer, A.5    Pochanard, P.6
  • 25
    • 84923341318 scopus 로고    scopus 로고
    • Increased MAPK reactivation in early resistance to dabrafenib/ trametinib combination therapy of BRAF-mutant metastatic melanoma
    • Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib/ trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 2014; 5: 5694.
    • (2014) Nat Commun , vol.5 , pp. 5694
    • Long, G.V.1    Fung, C.2    Menzies, A.M.3    Pupo, G.M.4    Carlino, M.S.5    Hyman, J.6
  • 26
    • 0024404145 scopus 로고
    • GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours
    • Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692-6.
    • (1989) Nature , vol.340 , pp. 692-696
    • Landis, C.A.1    Masters, S.B.2    Spada, A.3    Pace, A.M.4    Bourne, H.R.5    Vallar, L.6
  • 27
    • 77955655753 scopus 로고    scopus 로고
    • The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways
    • Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010; 29: 4567-75.
    • (2010) Oncogene , vol.29 , pp. 4567-4575
    • Wilson, C.H.1    McIntyre, R.E.2    Arends, M.J.3    Adams, D.J.4
  • 28
    • 84933040790 scopus 로고    scopus 로고
    • Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
    • Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-67.
    • (2015) Cancer Discov , vol.5 , pp. 358-367
    • Ahronian, L.G.1    Sennott, E.M.2    Van Allen, E.M.3    Wagle, N.4    Kwak, E.L.5    Faris, J.E.6
  • 29
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
    • (2012) Nature , vol.487 , pp. 330-337
    • Cancer Genome Atlas, N.1
  • 30
    • 84941350733 scopus 로고    scopus 로고
    • Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
    • Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015; 162: 1271-85.
    • (2015) Cell , vol.162 , pp. 1271-1285
    • Hugo, W.1    Shi, H.2    Sun, L.3    Piva, M.4    Song, C.5    Kong, X.6
  • 31
    • 55949099916 scopus 로고    scopus 로고
    • Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
    • Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, Arribas J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 2008; 99: 1607-12.
    • (2008) Br J Cancer , vol.99 , pp. 1607-1612
    • Vilar, E.1    Scaltriti, M.2    Balmana, J.3    Saura, C.4    Guzman, M.5    Arribas, J.6
  • 32
    • 84949009842 scopus 로고    scopus 로고
    • Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
    • Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS ONE 2015; 10: e0140712.
    • (2015) Plos ONE , vol.10
    • Lanman, R.B.1    Mortimer, S.A.2    Zill, O.A.3    Sebisanovic, D.4    Lopez, R.5    Blau, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.